ES3014398T3 - Compositions for treating pathological calcification and ossification - Google Patents

Compositions for treating pathological calcification and ossification Download PDF

Info

Publication number
ES3014398T3
ES3014398T3 ES14751154T ES14751154T ES3014398T3 ES 3014398 T3 ES3014398 T3 ES 3014398T3 ES 14751154 T ES14751154 T ES 14751154T ES 14751154 T ES14751154 T ES 14751154T ES 3014398 T3 ES3014398 T3 ES 3014398T3
Authority
ES
Spain
Prior art keywords
npp1
polypeptide
npp4
mutant
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14751154T
Other languages
English (en)
Spanish (es)
Inventor
Demetrios Braddock
Ronald Albright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Application granted granted Critical
Publication of ES3014398T3 publication Critical patent/ES3014398T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04001—Phosphodiesterase I (3.1.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES14751154T 2013-02-13 2014-02-12 Compositions for treating pathological calcification and ossification Active ES3014398T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361764297P 2013-02-13 2013-02-13
US201361904786P 2013-11-15 2013-11-15
PCT/US2014/015945 WO2014126965A2 (en) 2013-02-13 2014-02-12 Compositions and methods for treating pathological calcification and ossification

Publications (1)

Publication Number Publication Date
ES3014398T3 true ES3014398T3 (en) 2025-04-22

Family

ID=51354667

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14751154T Active ES3014398T3 (en) 2013-02-13 2014-02-12 Compositions for treating pathological calcification and ossification

Country Status (6)

Country Link
US (7) US9744219B2 (enExample)
EP (2) EP2956163B1 (enExample)
JP (4) JP6894664B2 (enExample)
ES (1) ES3014398T3 (enExample)
PL (1) PL2956163T3 (enExample)
WO (1) WO2014126965A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2956163T3 (pl) * 2013-02-13 2025-04-14 Yale University Kompozycje do leczenia patologicznego zwapnienia i kostnienia
ES2899895T3 (es) * 2014-12-19 2022-03-15 Inozyme Pharma Inc Procedimientos de tratamiento de calcificación tisular
JP6995627B2 (ja) * 2015-05-19 2022-02-04 イエール ユニバーシティ 病的石灰化状態を治療するための組成物およびそれを使用する方法
JP2018537093A (ja) 2015-11-20 2018-12-20 イエール ユニバーシティ 異所性石灰化障害を治療するための組成物およびそれを使用する方法
US11364284B2 (en) 2016-06-16 2022-06-21 Inozyme Pharma, Inc. Methods of treating myointimal proliferation
US11390859B2 (en) 2016-08-05 2022-07-19 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
JP7511469B2 (ja) 2017-09-27 2024-07-05 イノザイム ファーマ， インコーポレイテッド 組換えエクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ（ｎｐｐ１）を使用して心血管機能を改善し、心血管疾患を処置するための方法。
EP3790628A4 (en) * 2018-05-08 2022-03-09 Yale University COMPOSITIONS AND METHODS FOR REDUCING THE PROGRESSION OF NEPHROLITHIASIS
EP3844280A4 (en) 2018-08-31 2022-09-14 Yale University ENPP1 POLYPEPTIDES AND METHODS OF USE
BR112022024958A2 (pt) 2020-06-09 2022-12-27 Inozyme Pharma Inc Proteínas enpp1 solúveis e usos das mesmas
TW202216186A (zh) * 2020-07-02 2022-05-01 美商伊諾臻醫藥公司 用於治療同種異體移植物血管病變之組成物與方法
CA3195071A1 (en) * 2020-10-08 2022-04-14 Inozyme Pharma, Inc. Liver specific production of enpp1 or enpp3

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
US6043056A (en) 1998-11-06 2000-03-28 Incyte Pharmaceuticals, Inc. Cell surface glycoproteins
US7888372B2 (en) 2001-03-23 2011-02-15 National Institutes Of Health (Nih) Compositions and methods for modulating bone mineral deposition
AU2002258592A1 (en) * 2001-03-23 2002-11-25 The Burnham Institute Compositions and methods for modulating bone mineral deposition
EP1478772A2 (en) 2001-08-14 2004-11-24 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
US7323542B2 (en) 2002-02-21 2008-01-29 University Of Virginia Patent Foundation Bone targeting peptides
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
WO2011113027A2 (en) 2010-03-12 2011-09-15 Synageva Biopharma Corp Npp1 fusion proteins
AU2011362576B2 (en) 2011-03-11 2017-06-08 Alexion Pharmaceuticals, Inc. NPP1 fusion proteins
PL2956163T3 (pl) * 2013-02-13 2025-04-14 Yale University Kompozycje do leczenia patologicznego zwapnienia i kostnienia
ES2899895T3 (es) * 2014-12-19 2022-03-15 Inozyme Pharma Inc Procedimientos de tratamiento de calcificación tisular
JP6995627B2 (ja) 2015-05-19 2022-02-04 イエール ユニバーシティ 病的石灰化状態を治療するための組成物およびそれを使用する方法

Also Published As

Publication number Publication date
WO2014126965A3 (en) 2014-10-09
US20170252414A1 (en) 2017-09-07
JP7420766B2 (ja) 2024-01-23
HK1214952A1 (en) 2016-08-12
EP2956163A2 (en) 2015-12-23
JP2024026704A (ja) 2024-02-28
US10624958B2 (en) 2020-04-21
JP2021143202A (ja) 2021-09-24
JP6944977B2 (ja) 2021-10-06
US10052367B2 (en) 2018-08-21
US20170333533A1 (en) 2017-11-23
JP2016509023A (ja) 2016-03-24
US9744219B2 (en) 2017-08-29
PL2956163T3 (pl) 2025-04-14
US9913881B2 (en) 2018-03-13
EP2956163A4 (en) 2017-03-22
WO2014126965A2 (en) 2014-08-21
JP6894664B2 (ja) 2021-06-30
JP2019196392A (ja) 2019-11-14
US20150359858A1 (en) 2015-12-17
US20220152163A1 (en) 2022-05-19
EP4523757A3 (en) 2025-07-16
US11266722B2 (en) 2022-03-08
EP2956163B1 (en) 2024-11-27
US20170354719A1 (en) 2017-12-14
US20180318401A1 (en) 2018-11-08
EP4523757A2 (en) 2025-03-19
US20200237882A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
ES3014398T3 (en) Compositions for treating pathological calcification and ossification
ES2983910T3 (es) Composiciones para tratar afecciones patológicas de calcificación y métodos que usan las mismas
US9234191B2 (en) Cytotoxic ribonuclease variants
ES2510551T3 (es) Termoestabilización de proteínas
Aspatwar et al. Carbonic anhydrase related protein VIII and its role in neurodegeneration and cancer
US20180230234A1 (en) Inhibition of the complement system
ES2291010T3 (es) Enzimas fosfodiesterasas.
HK40123811A (en) Compositions and methods for treating pathological calcification and ossification
ES2328448T7 (es) 16836, un miembro de la familia de la fosfolipasa c humana y sus usos.
HK1214952B (en) Compositions for treating pathological calcification and ossification
Jiang et al. Crystal structures of human C4. 4A reveal the unique association of Ly6/uPAR/α-neurotoxin domain
AU2003297492A1 (en) Candida kefyr cytosine deaminase